3r90 - Revision history

OCA at 10:53, 21 February 2024

OCA — Wed, 21 Feb 2024 10:53:03 GMT

←Older revision		Revision as of 10:53, 21 February 2024
Line 3:		Line 3:
	<StructureSection load='3r90' size='340' side='right'caption='[[3r90]], [[Resolution\|resolution]] 1.70Å' scene=''>		<StructureSection load='3r90' size='340' side='right'caption='[[3r90]], [[Resolution\|resolution]] 1.70Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[3r90]] is a 12 chain structure with sequence from [https://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3R90 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3R90 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[3r90]] is a 12 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3R90 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3R90 FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>, <scene name='pdbligand=UNX:UNKNOWN+ATOM+OR+ION'>UNX</scene>~~</td></tr>~~	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 1.7Å</td></tr>
-	~~<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">MCTS1, MCT1 ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])~~</td></tr>	+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>, <scene name='pdbligand=UNX:UNKNOWN+ATOM+OR+ION'>UNX</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3r90 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3r90 OCA], [https://pdbe.org/3r90 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3r90 RCSB], [https://www.ebi.ac.uk/pdbsum/3r90 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3r90 ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3r90 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3r90 OCA], [https://pdbe.org/3r90 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3r90 RCSB], [https://www.ebi.ac.uk/pdbsum/3r90 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3r90 ProSAT]</span></td></tr>
	</table>		</table>
	== Function ==		== Function ==
-	[[https://www.uniprot.org/uniprot/MCTS1_HUMAN MCTS1_HUMAN]] Anti-oncogene that play a role in cell cycle regulation; decreases cell doubling time and anchorage-dependent growth; shortens the duration of G1 transit time and G1/S transition. When constituvely expressed, increases CDK4 and CDK6 kinases activity and CCND1/cyclin D1 protein level, as well as G1 cyclin/CDK complex formation. Plays a role as translation enhancer; Recruits the density-regulated protein/DENR and binds to the cap complex of the 5'-terminus of mRNAs, subsequently altering the mRNA translation profile; Up-regulates protein levels of BCL2L2, TFDP1, MRE11A, CCND1 and E2F1, while mRNA levels remains constant. Hyperactivates DNA damage signaling pathway; increased gamma-irradiation-induced phosphorylation of histone H2AX, and induces damage foci formation. Increases the overall number of chromosomal abnormalities such as larger chromosomes formation and multiples chromosomal fusions when overexpressed in gamma-irradiated cells. May play a role in promoting lymphoid tumor development: lymphoid cell lines overexpressing MCTS1 exhibit increased growth rates and display increased protection against apoptosis. May contribute to the pathogenesis and progression of breast cancer via promotion of angiogenesis through the decline of inhibitory THBS1/thrombospondin-1, and inhibition of apoptosis. Involved in the process of proteasome degradation to down-regulate Tumor suppressor p53/TP53 in breast cancer cell; Positively regulates phosphorylation of MAPK1 and MAPK3.<ref>PMID:9766643</ref> <ref>PMID:10440924</ref> <ref>PMID:11709712</ref> <ref>PMID:12637315</ref> <ref>PMID:16322206</ref> <ref>PMID:15897892</ref> <ref>PMID:16982740</ref> <ref>PMID:17416211</ref> <ref>PMID:17016429</ref>	+	[https://www.uniprot.org/uniprot/MCTS1_HUMAN MCTS1_HUMAN] Anti-oncogene that play a role in cell cycle regulation; decreases cell doubling time and anchorage-dependent growth; shortens the duration of G1 transit time and G1/S transition. When constituvely expressed, increases CDK4 and CDK6 kinases activity and CCND1/cyclin D1 protein level, as well as G1 cyclin/CDK complex formation. Plays a role as translation enhancer; Recruits the density-regulated protein/DENR and binds to the cap complex of the 5'-terminus of mRNAs, subsequently altering the mRNA translation profile; Up-regulates protein levels of BCL2L2, TFDP1, MRE11A, CCND1 and E2F1, while mRNA levels remains constant. Hyperactivates DNA damage signaling pathway; increased gamma-irradiation-induced phosphorylation of histone H2AX, and induces damage foci formation. Increases the overall number of chromosomal abnormalities such as larger chromosomes formation and multiples chromosomal fusions when overexpressed in gamma-irradiated cells. May play a role in promoting lymphoid tumor development: lymphoid cell lines overexpressing MCTS1 exhibit increased growth rates and display increased protection against apoptosis. May contribute to the pathogenesis and progression of breast cancer via promotion of angiogenesis through the decline of inhibitory THBS1/thrombospondin-1, and inhibition of apoptosis. Involved in the process of proteasome degradation to down-regulate Tumor suppressor p53/TP53 in breast cancer cell; Positively regulates phosphorylation of MAPK1 and MAPK3.<ref>PMID:9766643</ref> <ref>PMID:10440924</ref> <ref>PMID:11709712</ref> <ref>PMID:12637315</ref> <ref>PMID:16322206</ref> <ref>PMID:15897892</ref> <ref>PMID:16982740</ref> <ref>PMID:17416211</ref> <ref>PMID:17016429</ref>
-	~~<div style="background-color:#fffaf0;">~~	+
-	~~== Publication Abstract from PubMed ==~~	+
-	A strategy of rationally engineering protein surfaces with the aim of obtaining mutants that are distinctly more susceptible to crystallization than the wild-type protein has previously been suggested. The strategy relies on replacing small clusters of two to three surface residues characterized by high conformational entropy with alanines. This surface entropy reduction (or SER) method has proven to be an effective salvage pathway for proteins that are difficult to crystallize. Here, a systematic comparison of the efficacy of using Ala, His, Ser, Thr and Tyr to replace high-entropy residues is reported. A total of 40 mutants were generated and screened using two different procedures. The results reaffirm that alanine is a particularly good choice for a replacement residue and identify tyrosines and threonines as additional candidates that have considerable potential to mediate crystal contacts. The propensity of these mutants to form crystals in alternative screens in which the normal crystallization reservoir solutions were replaced with 1.5 M NaCl was also examined. The results were impressive: more than half of the mutants yielded a larger number of crystals with salt as the reservoir solution. This method greatly increased the variety of conditions that yielded crystals. Taken together, these results suggest a powerful crystallization strategy that combines surface engineering with efficient screening using standard and alternate reservoir solutions.	+
-		+
-	Protein crystallization by surface entropy reduction: optimization of the SER strategy.,Cooper DR, Boczek T, Grelewska K, Pinkowska M, Sikorska M, Zawadzki M, Derewenda Z Acta Crystallogr D Biol Crystallogr. 2007 May;63(Pt 5):636-45. Epub 2007, Apr 21. PMID:17452789<ref>PMID:17452789</ref>	+
-		+
-	~~From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>~~	+
-	~~</div>~~	+
-	~~<div class="pdbe-citations 3r90" style="background-color:#fffaf0;"></div~~>	+
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Human~~]]	+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Arrowsmith~~, C H~~]]	+	[[Category: Arrowsmith CH]]
-	[[Category: Bountra, C]]	+	[[Category: Bountra C]]
-	[[Category: Dimov, S]]	+	[[Category: Dimov S]]
-	[[Category: Edwards~~, A M~~]]	+	[[Category: Edwards AM]]
-	[[Category: Hong, B]]	+	[[Category: Hong B]]
-	[[Category: Park, H]]	+	[[Category: Park H]]
-	~~[[Category: Structural genomic~~]]	+	[[Category: Tempel W]]
-	[[Category: Tempel, W]]	+	[[Category: Tong Y]]
-	[[Category: Tong, Y]]	+	[[Category: Weigelt J]]
-	[[Category: Weigelt, J]]	+	[[Category: Wernimont AK]]
-	[[Category: Wernimont~~, A K]]~~	+
-	~~[[Category: Rna binding protein]]~~	+
-	~~[[Category: Sgc]]~~	+
-	~~[[Category: Surface entropy reduction~~]]	+

OCA at 05:53, 15 June 2022

OCA — Wed, 15 Jun 2022 05:53:44 GMT

←Older revision		Revision as of 05:53, 15 June 2022
Line 1:		Line 1:

	==Crystal structure of Malignant T cell-amplified sequence 1 protein==		==Crystal structure of Malignant T cell-amplified sequence 1 protein==
-	<StructureSection load='3r90' size='340' side='right' caption='[[3r90]], [[Resolution\|resolution]] 1.70Å' scene=''>	+	<StructureSection load='3r90' size='340' side='right'caption='[[3r90]], [[Resolution\|resolution]] 1.70Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[3r90]] is a 12 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3R90 OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=3R90 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[3r90]] is a 12 chain structure with sequence from [https://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3R90 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3R90 FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>, <scene name='pdbligand=UNX:UNKNOWN+ATOM+OR+ION'>UNX</scene></td></tr>	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>, <scene name='pdbligand=UNX:UNKNOWN+ATOM+OR+ION'>UNX</scene></td></tr>
-	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">MCTS1, MCT1 ([~~http~~://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>	+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">MCTS1, MCT1 ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=3r90 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3r90 OCA], [~~http~~://pdbe.org/3r90 PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=3r90 RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/3r90 PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=3r90 ProSAT]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3r90 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3r90 OCA], [https://pdbe.org/3r90 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3r90 RCSB], [https://www.ebi.ac.uk/pdbsum/3r90 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3r90 ProSAT]</span></td></tr>
	</table>		</table>
	== Function ==		== Function ==
-	[[~~http~~://www.uniprot.org/uniprot/MCTS1_HUMAN MCTS1_HUMAN]] Anti-oncogene that play a role in cell cycle regulation; decreases cell doubling time and anchorage-dependent growth; shortens the duration of G1 transit time and G1/S transition. When constituvely expressed, increases CDK4 and CDK6 kinases activity and CCND1/cyclin D1 protein level, as well as G1 cyclin/CDK complex formation. Plays a role as translation enhancer; Recruits the density-regulated protein/DENR and binds to the cap complex of the 5'-terminus of mRNAs, subsequently altering the mRNA translation profile; Up-regulates protein levels of BCL2L2, TFDP1, MRE11A, CCND1 and E2F1, while mRNA levels remains constant. Hyperactivates DNA damage signaling pathway; increased gamma-irradiation-induced phosphorylation of histone H2AX, and induces damage foci formation. Increases the overall number of chromosomal abnormalities such as larger chromosomes formation and multiples chromosomal fusions when overexpressed in gamma-irradiated cells. May play a role in promoting lymphoid tumor development: lymphoid cell lines overexpressing MCTS1 exhibit increased growth rates and display increased protection against apoptosis. May contribute to the pathogenesis and progression of breast cancer via promotion of angiogenesis through the decline of inhibitory THBS1/thrombospondin-1, and inhibition of apoptosis. Involved in the process of proteasome degradation to down-regulate Tumor suppressor p53/TP53 in breast cancer cell; Positively regulates phosphorylation of MAPK1 and MAPK3.<ref>PMID:9766643</ref> <ref>PMID:10440924</ref> <ref>PMID:11709712</ref> <ref>PMID:12637315</ref> <ref>PMID:16322206</ref> <ref>PMID:15897892</ref> <ref>PMID:16982740</ref> <ref>PMID:17416211</ref> <ref>PMID:17016429</ref>	+	[[https://www.uniprot.org/uniprot/MCTS1_HUMAN MCTS1_HUMAN]] Anti-oncogene that play a role in cell cycle regulation; decreases cell doubling time and anchorage-dependent growth; shortens the duration of G1 transit time and G1/S transition. When constituvely expressed, increases CDK4 and CDK6 kinases activity and CCND1/cyclin D1 protein level, as well as G1 cyclin/CDK complex formation. Plays a role as translation enhancer; Recruits the density-regulated protein/DENR and binds to the cap complex of the 5'-terminus of mRNAs, subsequently altering the mRNA translation profile; Up-regulates protein levels of BCL2L2, TFDP1, MRE11A, CCND1 and E2F1, while mRNA levels remains constant. Hyperactivates DNA damage signaling pathway; increased gamma-irradiation-induced phosphorylation of histone H2AX, and induces damage foci formation. Increases the overall number of chromosomal abnormalities such as larger chromosomes formation and multiples chromosomal fusions when overexpressed in gamma-irradiated cells. May play a role in promoting lymphoid tumor development: lymphoid cell lines overexpressing MCTS1 exhibit increased growth rates and display increased protection against apoptosis. May contribute to the pathogenesis and progression of breast cancer via promotion of angiogenesis through the decline of inhibitory THBS1/thrombospondin-1, and inhibition of apoptosis. Involved in the process of proteasome degradation to down-regulate Tumor suppressor p53/TP53 in breast cancer cell; Positively regulates phosphorylation of MAPK1 and MAPK3.<ref>PMID:9766643</ref> <ref>PMID:10440924</ref> <ref>PMID:11709712</ref> <ref>PMID:12637315</ref> <ref>PMID:16322206</ref> <ref>PMID:15897892</ref> <ref>PMID:16982740</ref> <ref>PMID:17416211</ref> <ref>PMID:17016429</ref>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 24:		Line 24:
	</StructureSection>		</StructureSection>
	[[Category: Human]]		[[Category: Human]]
		+	[[Category: Large Structures]]
	[[Category: Arrowsmith, C H]]		[[Category: Arrowsmith, C H]]
	[[Category: Bountra, C]]		[[Category: Bountra, C]]

OCA at 07:40, 5 August 2016

OCA — Fri, 05 Aug 2016 07:40:52 GMT

←Older revision		Revision as of 07:40, 5 August 2016
Line 1:		Line 1:
		+
	==Crystal structure of Malignant T cell-amplified sequence 1 protein==		==Crystal structure of Malignant T cell-amplified sequence 1 protein==
	<StructureSection load='3r90' size='340' side='right' caption='[[3r90]], [[Resolution\|resolution]] 1.70Å' scene=''>		<StructureSection load='3r90' size='340' side='right' caption='[[3r90]], [[Resolution\|resolution]] 1.70Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[3r90]] is a 12 chain structure with sequence from [http://en.wikipedia.org/wiki/~~Homo_sapiens Homo sapiens~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3R90 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3R90 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[3r90]] is a 12 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3R90 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3R90 FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>, <scene name='pdbligand=UNX:UNKNOWN+ATOM+OR+ION'>UNX</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>, <scene name='pdbligand=UNX:UNKNOWN+ATOM+OR+ION'>UNX</scene></td></tr>
-	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">MCTS1, MCT1 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 ~~Homo sapiens~~])</td></tr>	+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">MCTS1, MCT1 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3r90 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3r90 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3r90 RCSB], [http://www.ebi.ac.uk/pdbsum/3r90 PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3r90 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3r90 OCA], [http://pdbe.org/3r90 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=3r90 RCSB], [http://www.ebi.ac.uk/pdbsum/3r90 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=3r90 ProSAT]</span></td></tr>
	</table>		</table>
	== Function ==		== Function ==
Line 17:		Line 18:
	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>		From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
	</div>		</div>
		+	<div class="pdbe-citations 3r90" style="background-color:#fffaf0;"></div>
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Homo sapiens~~]]	+	[[Category: Human]]
	[[Category: Arrowsmith, C H]]		[[Category: Arrowsmith, C H]]
	[[Category: Bountra, C]]		[[Category: Bountra, C]]

OCA at 00:22, 25 December 2014

OCA — Thu, 25 Dec 2014 00:22:06 GMT

←Older revision		Revision as of 00:22, 25 December 2014
Line 7:		Line 7:
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3r90 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3r90 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3r90 RCSB], [http://www.ebi.ac.uk/pdbsum/3r90 PDBsum]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3r90 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3r90 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3r90 RCSB], [http://www.ebi.ac.uk/pdbsum/3r90 PDBsum]</span></td></tr>
	</table>		</table>
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/MCTS1_HUMAN MCTS1_HUMAN]] Anti-oncogene that play a role in cell cycle regulation; decreases cell doubling time and anchorage-dependent growth; shortens the duration of G1 transit time and G1/S transition. When constituvely expressed, increases CDK4 and CDK6 kinases activity and CCND1/cyclin D1 protein level, as well as G1 cyclin/CDK complex formation. Plays a role as translation enhancer; Recruits the density-regulated protein/DENR and binds to the cap complex of the 5'-terminus of mRNAs, subsequently altering the mRNA translation profile; Up-regulates protein levels of BCL2L2, TFDP1, MRE11A, CCND1 and E2F1, while mRNA levels remains constant. Hyperactivates DNA damage signaling pathway; increased gamma-irradiation-induced phosphorylation of histone H2AX, and induces damage foci formation. Increases the overall number of chromosomal abnormalities such as larger chromosomes formation and multiples chromosomal fusions when overexpressed in gamma-irradiated cells. May play a role in promoting lymphoid tumor development: lymphoid cell lines overexpressing MCTS1 exhibit increased growth rates and display increased protection against apoptosis. May contribute to the pathogenesis and progression of breast cancer via promotion of angiogenesis through the decline of inhibitory THBS1/thrombospondin-1, and inhibition of apoptosis. Involved in the process of proteasome degradation to down-regulate Tumor suppressor p53/TP53 in breast cancer cell; Positively regulates phosphorylation of MAPK1 and MAPK3.<ref>PMID:9766643</ref> <ref>PMID:10440924</ref> <ref>PMID:11709712</ref> <ref>PMID:12637315</ref> <ref>PMID:16322206</ref> <ref>PMID:15897892</ref> <ref>PMID:16982740</ref> <ref>PMID:17416211</ref> <ref>PMID:17016429</ref>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==

OCA at 11:01, 19 December 2014

OCA — Fri, 19 Dec 2014 11:01:14 GMT

←Older revision		Revision as of 11:01, 19 December 2014
Line 1:		Line 1:
-	~~{{STRUCTURE_3r90\| PDB=3r90 \| SCENE= }}~~	+	==Crystal structure of Malignant T cell-amplified sequence 1 protein==
-	===Crystal structure of Malignant T cell-amplified sequence 1 protein===	+	<StructureSection load='3r90' size='340' side='right' caption='[[3r90]], [[Resolution\|resolution]] 1.70Å' scene=''>
-	~~{{ABSTRACT_PUBMED_17452789}}~~	+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[3r90]] is a 12 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3R90 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3R90 FirstGlance]. <br>
		+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>, <scene name='pdbligand=UNX:UNKNOWN+ATOM+OR+ION'>UNX</scene></td></tr>
		+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">MCTS1, MCT1 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 Homo sapiens])</td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3r90 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3r90 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3r90 RCSB], [http://www.ebi.ac.uk/pdbsum/3r90 PDBsum]</span></td></tr>
		+	</table>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	A strategy of rationally engineering protein surfaces with the aim of obtaining mutants that are distinctly more susceptible to crystallization than the wild-type protein has previously been suggested. The strategy relies on replacing small clusters of two to three surface residues characterized by high conformational entropy with alanines. This surface entropy reduction (or SER) method has proven to be an effective salvage pathway for proteins that are difficult to crystallize. Here, a systematic comparison of the efficacy of using Ala, His, Ser, Thr and Tyr to replace high-entropy residues is reported. A total of 40 mutants were generated and screened using two different procedures. The results reaffirm that alanine is a particularly good choice for a replacement residue and identify tyrosines and threonines as additional candidates that have considerable potential to mediate crystal contacts. The propensity of these mutants to form crystals in alternative screens in which the normal crystallization reservoir solutions were replaced with 1.5 M NaCl was also examined. The results were impressive: more than half of the mutants yielded a larger number of crystals with salt as the reservoir solution. This method greatly increased the variety of conditions that yielded crystals. Taken together, these results suggest a powerful crystallization strategy that combines surface engineering with efficient screening using standard and alternate reservoir solutions.

-	~~==Function==~~	+	Protein crystallization by surface entropy reduction: optimization of the SER strategy.,Cooper DR, Boczek T, Grelewska K, Pinkowska M, Sikorska M, Zawadzki M, Derewenda Z Acta Crystallogr D Biol Crystallogr. 2007 May;63(Pt 5):636-45. Epub 2007, Apr 21. PMID:17452789<ref>PMID:17452789</ref>
-	~~[[http~~:~~//www.uniprot.org/uniprot/MCTS1_HUMAN MCTS1_HUMAN]] Anti-oncogene that play a role in cell cycle regulation; decreases cell doubling time and anchorage-dependent growth; shortens~~ the ~~duration of G1 transit time and G1/S transition~~. ~~When constituvely expressed~~, ~~increases CDK4 and CDK6 kinases activity and CCND1/cyclin D1 protein level~~, ~~as well as G1 cyclin/CDK complex formation. Plays a role as translation enhancer; Recruits the density-regulated protein/DENR and binds to the cap complex of the 5'-terminus of mRNAs~~, ~~subsequently altering the mRNA translation profile; Up-regulates protein levels of BCL2L2~~, ~~TFDP1~~, ~~MRE11A~~, ~~CCND1 and E2F1~~, ~~while mRNA levels remains constant~~. ~~Hyperactivates DNA damage signaling pathway~~; ~~increased gamma~~-~~irradiation-induced phosphorylation of histone H2AX, and induces damage foci formation~~. Increases the overall number of chromosomal abnormalities such as larger chromosomes formation and multiples chromosomal fusions when overexpressed in gamma-irradiated cells. May play a role in promoting lymphoid tumor development: lymphoid cell lines overexpressing MCTS1 exhibit increased growth rates and display increased protection against apoptosis. May contribute to the pathogenesis and progression of breast cancer via promotion of angiogenesis through the decline of inhibitory THBS1/thrombospondin-1, ~~and inhibition of apoptosis~~. ~~Involved in the process of proteasome degradation to down-regulate Tumor suppressor p53/TP53 in breast cancer cell; Positively regulates phosphorylation of MAPK1 and MAPK3.<ref>~~PMID:~~9766643</ref> <ref>PMID:10440924</ref> <ref>PMID:11709712</ref> <ref>PMID:12637315</ref> <ref>PMID:16322206</ref> <ref>PMID:15897892</ref> <ref>PMID:16982740</ref> <ref>PMID:17416211</ref>~~ <ref>PMID:~~17016429~~</ref>	+

-	~~==About this Structure==~~	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	~~[[3r90]] is~~ a ~~12 chain structure with sequence from [http://en~~.~~wikipedia~~.~~org/wiki/Homo_sapiens Homo sapiens]~~. ~~Full crystallographic information is available from [http:~~/~~/oca.weizmann.ac.il/oca-bin/ocashort?id=3R90 OCA].~~	+	</div>
-		+	== References ==
-	==~~Reference~~==	+	<references/>
-	~~<ref group="xtra">PMID:017452789</ref>~~<references ~~group="xtra"~~/><~~references~~/>	+	__TOC__
		+	</StructureSection>
	[[Category: Homo sapiens]]		[[Category: Homo sapiens]]
-	[[Category: Arrowsmith, C H.]]	+	[[Category: Arrowsmith, C H]]
-	[[Category: Bountra, C.]]	+	[[Category: Bountra, C]]
-	[[Category: Dimov, S.]]	+	[[Category: Dimov, S]]
-	[[Category: Edwards, A M.]]	+	[[Category: Edwards, A M]]
-	[[Category: Hong, B.]]	+	[[Category: Hong, B]]
-	[[Category: Park, H.]]	+	[[Category: Park, H]]
-	[[Category: ~~SGC,~~ Structural ~~Genomics Consortium.~~]]	+	[[Category: Structural genomic]]
-	[[Category: Tempel, W.]]	+	[[Category: Tempel, W]]
-	[[Category: Tong, Y.]]	+	[[Category: Tong, Y]]
-	[[Category: Weigelt, J.]]	+	[[Category: Weigelt, J]]
-	[[Category: Wernimont, A K.]]	+	[[Category: Wernimont, A K]]
	[[Category: Rna binding protein]]		[[Category: Rna binding protein]]
	[[Category: Sgc]]		[[Category: Sgc]]
-	[[Category: Structural genomics consortium]]
	[[Category: Surface entropy reduction]]		[[Category: Surface entropy reduction]]

OCA at 08:02, 16 May 2013

OCA — Thu, 16 May 2013 08:02:07 GMT

←Older revision		Revision as of 08:02, 16 May 2013
Line 1:		Line 1:
-	[[Image:3r90.jpg\|left\|200px]]
-
-	<!--
-	The line below this paragraph, containing "STRUCTURE_3r90", creates the "Structure Box" on the page.
-	You may change the PDB parameter (which sets the PDB file loaded into the applet)
-	or the SCENE parameter (which sets the initial scene displayed when the page is loaded),
-	or leave the SCENE parameter empty for the default display.
-	-->
	{{STRUCTURE_3r90\| PDB=3r90 \| SCENE= }}		{{STRUCTURE_3r90\| PDB=3r90 \| SCENE= }}
-
	===Crystal structure of Malignant T cell-amplified sequence 1 protein===		===Crystal structure of Malignant T cell-amplified sequence 1 protein===
		+	{{ABSTRACT_PUBMED_17452789}}

-		+	==Function==
-	<!--	+	[[http://www.uniprot.org/uniprot/MCTS1_HUMAN MCTS1_HUMAN]] Anti-oncogene that play a role in cell cycle regulation; decreases cell doubling time and anchorage-dependent growth; shortens the duration of G1 transit time and G1/S transition. When constituvely expressed, increases CDK4 and CDK6 kinases activity and CCND1/cyclin D1 protein level, as well as G1 cyclin/CDK complex formation. Plays a role as translation enhancer; Recruits the density-regulated protein/DENR and binds to the cap complex of the 5'-terminus of mRNAs, subsequently altering the mRNA translation profile; Up-regulates protein levels of BCL2L2, TFDP1, MRE11A, CCND1 and E2F1, while mRNA levels remains constant. Hyperactivates DNA damage signaling pathway; increased gamma-irradiation-induced phosphorylation of histone H2AX, and induces damage foci formation. Increases the overall number of chromosomal abnormalities such as larger chromosomes formation and multiples chromosomal fusions when overexpressed in gamma-irradiated cells. May play a role in promoting lymphoid tumor development: lymphoid cell lines overexpressing MCTS1 exhibit increased growth rates and display increased protection against apoptosis. May contribute to the pathogenesis and progression of breast cancer via promotion of angiogenesis through the decline of inhibitory THBS1/thrombospondin-1, and inhibition of apoptosis. Involved in the process of proteasome degradation to down-regulate Tumor suppressor p53/TP53 in breast cancer cell; Positively regulates phosphorylation of MAPK1 and MAPK3.<ref>PMID:9766643</ref> <ref>PMID:10440924</ref> <ref>PMID:11709712</ref> <ref>PMID:12637315</ref> <ref>PMID:16322206</ref> <ref>PMID:15897892</ref> <ref>PMID:16982740</ref> <ref>PMID:17416211</ref> <ref>PMID:17016429</ref>
-	~~The line below this paragraph~~, ~~{{ABSTRACT_PUBMED_17452789}}~~, ~~adds the Publication Abstract to the page~~	+
-	(as ~~it appears on PubMed at http:~~//~~www~~.~~pubmed.gov)~~, ~~where 17452789 is~~ the ~~PubMed ID~~ number.	+
-	-->	+
-	~~{{ABSTRACT_PUBMED_17452789}}~~	+

	==About this Structure==		==About this Structure==
Line 22:		Line 10:

	==Reference==		==Reference==
-	<ref group="xtra">PMID:~~17452789~~</ref><references group="xtra"/>	+	<ref group="xtra">PMID:017452789</ref><references group="xtra"/><references/>
	[[Category: Homo sapiens]]		[[Category: Homo sapiens]]
	[[Category: Arrowsmith, C H.]]		[[Category: Arrowsmith, C H.]]
Line 35:		Line 23:
	[[Category: Weigelt, J.]]		[[Category: Weigelt, J.]]
	[[Category: Wernimont, A K.]]		[[Category: Wernimont, A K.]]
		+	[[Category: Rna binding protein]]
		+	[[Category: Sgc]]
		+	[[Category: Structural genomics consortium]]
		+	[[Category: Surface entropy reduction]]

OCA at 05:28, 13 April 2011

OCA — Wed, 13 Apr 2011 05:28:19 GMT

←Older revision		Revision as of 05:28, 13 April 2011
Line 1:		Line 1:
-	~~'''Unreleased structure'''~~	+	[[Image:3r90.jpg\|left\|200px]]

-	The ~~entry 3r90~~ is ~~ON HOLD~~	+	<!--
		+	The line below this paragraph, containing "STRUCTURE_3r90", creates the "Structure Box" on the page.
		+	You may change the PDB parameter (which sets the PDB file loaded into the applet)
		+	or the SCENE parameter (which sets the initial scene displayed when the page is loaded),
		+	or leave the SCENE parameter empty for the default display.
		+	-->
		+	{{STRUCTURE_3r90\| PDB=3r90 \| SCENE= }}

-	~~Authors: Hong, B., Dimov, S., Tempel, W., Tong, Y., Wernimont, A.K., Arrowsmith, C.H., Edwards, A.M., Bountra, C., Weigelt, J., Park, H., Structural Genomics Consortium (SGC)~~	+	===Crystal structure of Malignant T cell-amplified sequence 1 protein===

-	~~Description~~: ~~Crystal structure of Malignant T cell~~-~~amplified~~ sequence ~~1 protein~~	+
		+	<!--
		+	The line below this paragraph, {{ABSTRACT_PUBMED_17452789}}, adds the Publication Abstract to the page
		+	(as it appears on PubMed at http://www.pubmed.gov), where 17452789 is the PubMed ID number.
		+	-->
		+	{{ABSTRACT_PUBMED_17452789}}
		+
		+	==About this Structure==
		+	[[3r90]] is a 12 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3R90 OCA].
		+
		+	==Reference==
		+	<ref group="xtra">PMID:17452789</ref><references group="xtra"/>
		+	[[Category: Homo sapiens]]
		+	[[Category: Arrowsmith, C H.]]
		+	[[Category: Bountra, C.]]
		+	[[Category: Dimov, S.]]
		+	[[Category: Edwards, A M.]]
		+	[[Category: Hong, B.]]
		+	[[Category: Park, H.]]
		+	[[Category: SGC, Structural Genomics Consortium.]]
		+	[[Category: Tempel, W.]]
		+	[[Category: Tong, Y.]]
		+	[[Category: Weigelt, J.]]
		+	[[Category: Wernimont, A K.]]

OCA: Protected "3r90" [edit=sysop:move=sysop]

OCA — Wed, 30 Mar 2011 07:52:17 GMT

Protected "3r90" [edit=sysop:move=sysop]

←Older revision

Revision as of 07:52, 30 March 2011

OCA: New page: '''Unreleased structure''' The entry 3r90 is ON HOLD Authors: Hong, B., Dimov, S., Tempel, W., Tong, Y., Wernimont, A.K., Arrowsmith, C.H., Edwards, A.M., Bountra, C., Weigelt, J., Park...

OCA — Wed, 30 Mar 2011 07:52:16 GMT

New page: '''Unreleased structure''' The entry 3r90 is ON HOLD Authors: Hong, B., Dimov, S., Tempel, W., Tong, Y., Wernimont, A.K., Arrowsmith, C.H., Edwards, A.M., Bountra, C., Weigelt, J., Park...

New page

'''Unreleased structure'''

The entry 3r90 is ON HOLD

Authors: Hong, B., Dimov, S., Tempel, W., Tong, Y., Wernimont, A.K., Arrowsmith, C.H., Edwards, A.M., Bountra, C., Weigelt, J., Park, H., Structural Genomics Consortium (SGC)

Description: Crystal structure of Malignant T cell-amplified sequence 1 protein